A Phase 3 interventional study of Placebo and 50 mg etanercept in Psoriasis, sponsored by Eli Lilly and Company. Completed at 101 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-28.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.
Among the 22 studies testing ixekizumab in Psoriasis, this one has the largest enrollment, is one of 3 that started in 2012, is one of 11 in phase 3, and was the 5th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
Singapore General Hospital · Sites in Singapore
Ages 22–90
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ages 70+
By country, each count listing its studies:
ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,346 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 156 across the 22 interventional studies. Of the 17 that completed or were terminated, 16 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
36 studies in Psoriasis by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 35 finished, 28 (80%) have results posted.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 3rd largest by enrollment, is one of 3 that started in 2012, is one of 15 in phase 3, and was the 7th registered.
Eli Lilly and Company’s Psoriasis studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing ixekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 36 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, participants are assigned to Dosing Regimen 2.
Drug: Placebo
Administered by SC injections twice weekly starting at Week 0 up to Week 12. At Week 12, arm is assigned to Dosing Regimen 2
Drug: 50 mg etanercept
Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 264.
Drug: 80 mg ixekizumab
Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, arm is assigned to Dosing Regimen 2.
Drug: 80 mg ixekizumab
Administered SC
Administered SC
Administered SC
Also known as: LY2439821
Number of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)
The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1.
Time frame: Week 12
Number of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 was defined as having an improvement of at least 75% in the PASI scores compared to baseline.
Time frame: Week 12
Number of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)
The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0) response was defined as a post-baseline sPGA score of 0.
Time frame: Week 12
Number of Participants Achieving ≥90% (PASI 90) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.
Time frame: Week 12
Number of Participants Achieving 100% (PASI 100) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.
Time frame: Week 12
Number of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]
The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Participants indicate their overall severity of itching from Psoriasis by circling the number that best describes the worst level of itching in the past 24 hours.
Time frame: Week 12
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
Time frame: Baseline, Week 12
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score
The NAPSI is a numeric, reproducible, objective tool used to evaluate the severity of fingernail bed psoriasis and fingernail matrix psoriasis by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed psoriasis: 0 (none) to 4 (psoriasis in 4 quadrants of the nail) and fingernail matrix psoriasis (0 to 4) depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed and fingernail matrix psoriasis in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, and the sum of all the fingernails is the total NAPSI score (range, 0 to 80). LS Means in NAPSI score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
Time frame: Baseline, Week 12
Percent of Body Surface Area (BSA) Involvement of Psoriasis
Percentage involvement of psoriasis on each participants body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand (including palm, fingers and thumb). LS Means in BSA were calculated using MMRM with baseline BSA as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
Time frame: Week 12
Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score
PSSI is a composite score ranging from 0 (best) to 72 (worst), derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of scalp area involved. LS Means in PSSI score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
Time frame: Baseline, Week 12
Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]
The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance \[initial, middle and late insomnia or hypersomnia\], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS Means in total QIDS-SR16 score were calculated using the analysis of covariance (ANCOVA) model with treatment, pooled center and baseline QIDS total score.
Time frame: Baseline, Week 12
Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)
The WPAI-PSO is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days. It has four domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as: each score \* 100 and ranged from 0 to 100. Higher scores indicate greater impairment in productivity. LS Means in each WPAI-PSO score were calculated using the ANCOVA model with treatment, pooled center and baseline WPAI-PSO score.
Time frame: Baseline, Week 12
Change From Baseline in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey, Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS Means in SF-36 score were calculated using the ANCOVA model with treatment, pooled center and baseline SF-36 score.
Time frame: Baseline, Week 12
Change From Baseline in Patient's Global Assessment of Disease Severity
The Patient's Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis "today" from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. LS Means in Patient's Global Assessment of Disease Severity score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
Time frame: Baseline, Week 12
Number of Participants Achieving Palmoplantar PASI of ≥50% (PPASI 50) Improvement
Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 50 were defined as having an improvement of at least 50% in the PPASI scores compared to baseline.
Time frame: Week 12
Number of Participants Achieving Palmoplantar PASI of ≥75% (PPASI 75) Improvement
Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 75 were defined as having an improvement of at least 75% in the PPASI scores compared to baseline.
Time frame: Week 12
Number of Participants Achieving Palmoplantar PASI of 100% (PPASI 100) Improvement
Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 100 were defined as having an improvement of 100% in the PPASI scores compared to baseline.
Time frame: Week 12
Number of Participants With Treatment-Emergent Anti-Ixekizumab Antibodies
The percentage of participants with treatment-emergent positive anti-ixekizumab antibodies at any time post-baseline were summarized by treatment group. Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies were calculated as: number of participants with an evaluable baseline sample and ≥1 evaluable post-baseline sample/number of participants in the analysis population \* 100.
Time frame: Week 12
| Milestone | Placebo | 50 mg Etanercept (ETN) | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) | PBO/IXE80Q4W | ETN/IXE80Q4W | IXE80Q4W/IXE80Q4W | IXE80Q2W/IXE80Q4W | PBO Follow-Up Period | ETN Follow-Up Period | IXE80Q4W Follow-Up Period | IXE80Q2W Follow-Up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 193 | 382 | 386 | 385 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 193 | 382 | 382 | 384 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 183 | 369 | 360 | 363 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 10 | 13 | 26 | 22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 4 | 9 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 3 | 8 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | 50 mg Etanercept (ETN) | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) | PBO/IXE80Q4W | ETN/IXE80Q4W | IXE80Q4W/IXE80Q4W | IXE80Q2W/IXE80Q4W | PBO Follow-Up Period | ETN Follow-Up Period | IXE80Q4W Follow-Up Period | IXE80Q2W Follow-Up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 183 | 369 | 360 | 362 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 0 | 0 | 0 | 0 | 183 | 369 | 360 | 362 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 135 | 256 | 244 | 255 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 48 | 113 | 116 | 107 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 16 | 34 | 43 | 30 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 11 | 30 | 29 | 27 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 6 | 17 | 23 | 18 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 6 | 14 | 10 | 11 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 3 | 5 | 5 | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 3 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Clinical relapse | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Parent/caregiver decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Missing disposition form | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | 50 mg Etanercept (ETN) | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) | PBO/IXE80Q4W | ETN/IXE80Q4W | IXE80Q4W/IXE80Q4W | IXE80Q2W/IXE80Q4W | PBO Follow-Up Period | ETN Follow-Up Period | IXE80Q4W Follow-Up Period | IXE80Q2W Follow-Up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 157 | 309 | 305 | 313 |
| Received at least one dose of study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 157 | 309 | 305 | 313 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 126 | 233 | 225 | 230 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 31 | 76 | 80 | 83 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 28 | 34 | 30 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 21 | 19 | 19 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 8 | 9 | 9 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 9 | 8 | 9 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 4 | 7 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 3 |
| Withdrew: Clinical relapse | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Entry criteria not met | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1.
| Participants | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Number of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA) | 13 | 159 | 291 | 310 |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 was defined as having an improvement of at least 75% in the PASI scores compared to baseline.
| Participants | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Number of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI) | 14 | 204 | 325 | 336 |
The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0) response was defined as a post-baseline sPGA score of 0.
| Participants | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Number of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA) | 0 | 33 | 139 | 155 |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.
| Participants | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Number of Participants Achieving ≥90% (PASI 90) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI) | 6 | 98 | 252 | 262 |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.
| Participants | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Number of Participants Achieving 100% (PASI 100) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI) | 0 | 28 | 135 | 145 |
The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Participants indicate their overall severity of itching from Psoriasis by circling the number that best describes the worst level of itching in the past 24 hours.
| Participants | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Number of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)] | 33 | 200 | 250 | 264 |
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
| Units on a Scale | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score | -1.7 ± 0.32 | -8.0 ± 0.23 | -9.6 ± 0.23 | -10.2 ± 0.23 |
The NAPSI is a numeric, reproducible, objective tool used to evaluate the severity of fingernail bed psoriasis and fingernail matrix psoriasis by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed psoriasis: 0 (none) to 4 (psoriasis in 4 quadrants of the nail) and fingernail matrix psoriasis (0 to 4) depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed and fingernail matrix psoriasis in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, and the sum of all the fingernails is the total NAPSI score (range, 0 to 80). LS Means in NAPSI score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
| Units on a Scale | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score | 1.6362 ± 1.0991 | -6.4015 ± 0.7716 | -9.9793 ± 0.7838 | -10.4145 ± 0.7820 |
Percentage involvement of psoriasis on each participants body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand (including palm, fingers and thumb). LS Means in BSA were calculated using MMRM with baseline BSA as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
| Percent | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Percent of Body Surface Area (BSA) Involvement of Psoriasis | -0.7 ± 1.03 | -16.4 ± 0.73 | -23.2 ± 0.73 | -23.2 ± 0.73 |
PSSI is a composite score ranging from 0 (best) to 72 (worst), derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of scalp area involved. LS Means in PSSI score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
| Units on a Scale | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score | -5.0 ± 0.53 | -15.9 ± 0.38 | -18.2 ± 0.38 | -18.8 ± 0.38 |
The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance \[initial, middle and late insomnia or hypersomnia\], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS Means in total QIDS-SR16 score were calculated using the analysis of covariance (ANCOVA) model with treatment, pooled center and baseline QIDS total score.
| Units on a Scale | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)] | -0.3 ± 0.20 | -0.5 ± 0.14 | -0.9 ± 0.14 | -1.3 ± 0.14 |
The WPAI-PSO is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days. It has four domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as: each score \* 100 and ranged from 0 to 100. Higher scores indicate greater impairment in productivity. LS Means in each WPAI-PSO score were calculated using the ANCOVA model with treatment, pooled center and baseline WPAI-PSO score.
| Units on a Scale | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Absenteeism Score | 0.0 ± 0.82 | -2.8 ± 0.62 | -2.0 ± 0.60 | -2.5 ± 0.61 |
| Activity Impairment Score | -2.5 ± 1.30 | -21.1 ± 0.91 | -23.3 ± 0.92 | -24.5 ± 0.92 |
| Presenteeism Score | -0.8 ± 1.37 | -16.4 ± 1.04 | -16.0 ± 1.01 | -18.1 ± 1.04 |
| Work Productively Loss Score | 0.6 ± 1.59 | -17.4 ± 1.20 | -16.7 ± 1.16 | -19.3 ± 1.19 |
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS Means in SF-36 score were calculated using the ANCOVA model with treatment, pooled center and baseline SF-36 score.
| Units on a Scale | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| PCS | -0.1993 ± 0.5077 | 3.1176 ± 0.3568 | 4.1143 ± 0.3587 | 3.9620 ± 0.3604 |
| MCS | 1.1305 ± 0.5768 | 2.6486 ± 0.4047 | 3.7961 ± 0.4074 | 4.2772 ± 0.4093 |
The Patient's Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis "today" from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. LS Means in Patient's Global Assessment of Disease Severity score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
| Units on a Scale | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Change From Baseline in Patient's Global Assessment of Disease Severity | -0.5 ± 0.08 | -2.3 ± 0.06 | -3.1 ± 0.06 | -3.1 ± 0.06 |
Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 50 were defined as having an improvement of at least 50% in the PPASI scores compared to baseline.
| Participants | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Number of Participants Achieving Palmoplantar PASI of ≥50% (PPASI 50) Improvement | 26 | 77 | 75 | 78 |
Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 75 were defined as having an improvement of at least 75% in the PPASI scores compared to baseline.
| Participants | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Number of Participants Achieving Palmoplantar PASI of ≥75% (PPASI 75) Improvement | 19 | 63 | 69 | 72 |
Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 100 were defined as having an improvement of 100% in the PPASI scores compared to baseline.
| Participants | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Number of Participants Achieving Palmoplantar PASI of 100% (PPASI 100) Improvement | 15 | 57 | 54 | 61 |
The percentage of participants with treatment-emergent positive anti-ixekizumab antibodies at any time post-baseline were summarized by treatment group. Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies were calculated as: number of participants with an evaluable baseline sample and ≥1 evaluable post-baseline sample/number of participants in the analysis population \* 100.
| Participants | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) |
|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Anti-Ixekizumab Antibodies | 2 | 8 | 52 | 23 |
Collected over Up to 288 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 5/193 (2.6%) | 40/193 (20.7%) |
| 50 mg Etanercept | — | 8/382 (2.1%) | 90/382 (23.6%) |
| 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | — | 6/382 (1.6%) | 115/382 (30.1%) |
| 80 mg Ixekizumab Dosing Regimen 1 (Q2W) | — | 9/384 (2.3%) | 123/384 (32%) |
| PBO/IXE80Q4W Long-Term Extension | — | 45/183 (24.6%) | 117/183 (63.9%) |
| ETN/IXE80Q4W Long-Term Extension | — | 71/369 (19.2%) | 240/369 (65%) |
| IXE80Q4W/IXE80Q4W Long-Term Extension | — | 82/360 (22.8%) | 236/360 (65.6%) |
| IXE80Q2W/IXE80Q4W Long-Term Extension | — | 55/362 (15.2%) | 249/362 (68.8%) |
| PBO Follow-Up Period | — | 5/157 (3.2%) | 9/157 (5.7%) |
| ETN Follow-Up Period | — | 5/309 (1.6%) | 23/309 (7.4%) |
| IXE80Q4W Follow-Up | — | 2/305 (0.7%) | 14/305 (4.6%) |
| IXE80Q2W Follow-Up | — | 6/313 (1.9%) | 15/313 (4.8%) |
| Event | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) | PBO/IXE80Q4W Long-Term Extension | ETN/IXE80Q4W Long-Term Extension | IXE80Q4W/IXE80Q4W Long-Term Extension | IXE80Q2W/IXE80Q4W Long-Term Extension | PBO Follow-Up Period | ETN Follow-Up Period | IXE80Q4W Follow-Up | IXE80Q2W Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/56 | 0/113 | 0/128 | 0/130 | 0/54 | 1/109 | 2/119 | 0/121 | 0/49 | 1/92 | 0/100 | 0/104 |
| CellulitisInfections and infestations | 1/193 | 0/382 | 0/382 | 0/384 | 3/183 | 4/369 | 3/360 | 1/362 | 0/157 | 0/309 | 0/305 | 0/313 |
| DiverticulitisInfections and infestations | 0/193 | 0/382 | 0/382 | 0/384 | 3/183 | 0/369 | 0/360 | 1/362 | 0/157 | 0/309 | 0/305 | 0/313 |
| CholelithiasisHepatobiliary disorders | 0/193 | 0/382 | 0/382 | 1/384 | 0/183 | 2/369 | 4/360 | 4/362 | 0/157 | 0/309 | 0/305 | 1/313 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/193 | 1/382 | 0/382 | 0/384 | 1/183 | 4/369 | 4/360 | 1/362 | 0/157 | 0/309 | 0/305 | 0/313 |
| Atrial fibrillationCardiac disorders | 0/193 | 0/382 | 0/382 | 0/384 | 2/183 | 3/369 | 0/360 | 0/362 | 0/157 | 0/309 | 0/305 | 0/313 |
| Myocardial infarctionCardiac disorders | 0/193 | 0/382 | 0/382 | 0/384 | 2/183 | 2/369 | 3/360 | 2/362 | 0/157 | 0/309 | 0/305 | 0/313 |
| CholecystitisHepatobiliary disorders | 0/193 | 0/382 | 0/382 | 0/384 | 2/183 | 0/369 | 0/360 | 1/362 | 0/157 | 0/309 | 0/305 | 1/313 |
| FallInjury, poisoning and procedural complications | 1/193 | 1/382 | 0/382 | 1/384 | 2/183 | 2/369 | 2/360 | 1/362 | 0/157 | 0/309 | 0/305 | 1/313 |
| Back painMusculoskeletal and connective tissue disorders | 0/193 | 0/382 | 0/382 | 0/384 | 2/183 | 0/369 | 1/360 | 0/362 | 0/157 | 0/309 | 0/305 | 0/313 |
| Event | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) | PBO/IXE80Q4W Long-Term Extension | ETN/IXE80Q4W Long-Term Extension | IXE80Q4W/IXE80Q4W Long-Term Extension | IXE80Q2W/IXE80Q4W Long-Term Extension | PBO Follow-Up Period | ETN Follow-Up Period | IXE80Q4W Follow-Up | IXE80Q2W Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 11/193 | 19/382 | 29/382 | 26/384 | 55/183 | 104/369 | 107/360 | 112/362 | 4/157 | 4/309 | 5/305 | 2/313 |
| Upper respiratory tract infectionInfections and infestations | 5/193 | 8/382 | 8/382 | 8/384 | 21/183 | 33/369 | 48/360 | 42/362 | 0/157 | 1/309 | 1/305 | 2/313 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/193 | 7/382 | 9/382 | 13/384 | 17/183 | 20/369 | 29/360 | 41/362 | 0/157 | 1/309 | 1/305 | 1/313 |
| Injection site reactionGeneral disorders | 3/193 | 42/382 | 43/382 | 37/384 | 18/183 | 24/369 | 34/360 | 24/362 | 0/157 | 0/309 | 0/305 | 0/313 |
| HypertensionVascular disorders | 2/193 | 9/382 | 3/382 | 5/384 | 20/183 | 30/369 | 30/360 | 26/362 | 1/157 | 2/309 | 0/305 | 0/313 |
| BronchitisInfections and infestations | 0/193 | 4/382 | 6/382 | 1/384 | 17/183 | 20/369 | 24/360 | 36/362 | 0/157 | 0/309 | 1/305 | 3/313 |
| SinusitisInfections and infestations | 2/193 | 1/382 | 1/382 | 4/384 | 16/183 | 10/369 | 28/360 | 27/362 | 0/157 | 1/309 | 1/305 | 1/313 |
| Back painMusculoskeletal and connective tissue disorders | 2/193 | 2/382 | 8/382 | 7/384 | 16/183 | 28/369 | 23/360 | 30/362 | 1/157 | 1/309 | 0/305 | 0/313 |
| HeadacheNervous system disorders | 5/193 | 11/382 | 16/382 | 16/384 | 9/183 | 30/369 | 23/360 | 27/362 | 0/157 | 2/309 | 1/305 | 2/313 |
| DiarrhoeaGastrointestinal disorders | 2/193 | 6/382 | 3/382 | 11/384 | 10/183 | 27/369 | 14/360 | 25/362 | 0/157 | 0/309 | 0/305 | 0/313 |
All randomized participants.
| Age, Categorical(Participants) | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 180 | 349 | 358 | 351 | 1238 |
| >=65 years | 13 | 33 | 28 | 34 | 108 |
| Sex: Female, Male(Participants) | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) | Total |
|---|---|---|---|---|---|
| Female | 56 | 113 | 128 | 131 | 428 |
| Male | 137 | 269 | 258 | 254 | 918 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 25 | 52 | 50 | 57 | 184 |
| Not Hispanic or Latino | 133 | 263 | 269 | 259 | 924 |
| Unknown or Not Reported | 35 | 67 | 67 | 69 | 238 |
| Race (NIH/OMB)(Participants) | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 4 | 4 | 1 | 10 |
| Asian | 7 | 11 | 11 | 12 | 41 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 | 4 | 6 |
| Black or African American | 8 | 10 | 9 | 5 | 32 |
| White | 176 | 351 | 360 | 361 | 1248 |
| More than one race | 1 | 5 | 1 | 2 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | 50 mg Etanercept | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) | Total |
|---|---|---|---|---|---|
| Argentina | 2 | 7 | 6 | 6 | 21 |
| Chile | 11 | 21 | 22 | 22 | 76 |
| Mexico | 1 | 2 | 1 | 1 | 5 |
| Bulgaria | 9 | 12 | 14 | 13 | 48 |
| Germany | 45 | 87 | 90 | 90 | 312 |
| Hungary | 18 | 31 | 31 | 33 | 113 |
| Poland | 5 | 10 | 11 | 13 | 39 |
| Russia | 11 | 22 | 20 | 24 | 77 |
| Canada | 22 | 44 | 44 | 42 | 152 |
| United States | 69 | 146 | 147 | 141 | 503 |
Showing the first 100 of 101 sites across 10 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2012 to primary completion in May 2014, 21 months.
Results were first posted in Oct 2016, 2 years 4 months after primary completion. A results delay was requested in Sep 2014.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 21 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab